VHH antibodies, also known as nanobodies, are derived from the variable domains of camelid heavy-chain-only antibodies. Due to their small size (~15 kDa), high solubility, and stability, VHHs are used as tools in therapeutic antibody engineering. Their ability to access cryptic or concave epitopes inaccessible to conventional IgG antibodies makes them especially useful in targeting complex antigens.
However, the small size of VHHs also results in rapid renal clearance, limiting their therapeutic half-life. To address this, VHHs can be fused with fusion partners such as IgG Fc domains or enzymes. These fusion strategies aim to:
Prolong serum half-life via FcRn-mediated recycling
Introduce immune effector functions (e.g., ADCC, CDC)
Deliver catalytic activity for targeted enzymatic functions
Fc fusion of VHHs is gaining momentum in therapeutic antibody development, with growing relevance across oncology, infectious disease, and enzyme replacement therapies. This approach aligns closely with services offered by Biointron’s VHH Antibody Discovery platform, which provides custom VHH library screening, humanization, and expression-ready constructs suitable for Fc or enzyme fusion engineering.
VHH Fc fusion refers to the genetic linkage of a single-domain VHH antibody to the Fc region of human IgG, typically IgG1 or IgG4. This design confers multiple functional enhancements:
Serum half-life extension: The Fc domain engages the neonatal Fc receptor (FcRn), which mediates endosomal recycling and protects the fusion protein from lysosomal degradation. As reported by Abdeldaim & Schindowski (2023), this FcRn interaction is highly pH-dependent and critical for IgG’s ~21-day half-life. Preclinical evidence confirms that VHH-Fc fusions persist in circulation significantly longer than monomeric VHHs. Serum concentrations of Fc-fused clones (e.g., B11-Fc and G3-Fc) remained detectable up to 14 days post-injection in mice, correlating with extended in vivo protection.1
Bivalent binding: Dimerization via the Fc region increases the functional valency of the VHH, improving avidity and overall binding stability.
Effector function capability: Depending on the Fc isotype and engineering, the fusion may trigger ADCC, CDC, or antibody-dependent cellular phagocytosis (ADCP). These functions are particularly valuable in tumor immunotherapy and targeted cell depletion.
Improved expression and purification: The Fc region enables high-yield production in mammalian systems and facilitates Protein A/G affinity purification.
Extended Half-Life
VHHs fused to Fc domains avoid rapid renal clearance due to increased molecular weight and FcRn engagement, enabling longer dosing intervals in therapeutic applications.
Improved Systemic Exposure
The fusion prolongs the systemic exposure of VHHs in circulation, enhancing therapeutic efficacy, especially in chronic and systemic conditions.
Effector Functions
Fc domains (especially IgG1) engage Fcγ receptors (FcγRs) and complement components to induce:
ADCC via FcγRIIIA on NK cells
CDC via C1q recruitment
ADCP via FcγRIIA on phagocytes
Enhanced Manufacturability
Fc fusion stabilizes folding, improves solubility, and increases yields in mammalian expression systems. Purification is simplified via Fc-specific resins.
In vivo studies have shown that fusing VHHs to Fc fragments significantly increases their in vivo protective efficacy. In a murine model of botulinum neurotoxin A (BoNT/A) challenge, VHH-Fc constructs demonstrated over 1000-fold greater protective activity compared to monomeric VHHs. For example, a single injection of 0.001 µg of the B11-Fc construct conferred full protection against a 5× LD50 BoNT/A dose, whereas monomers required over 100 µg for partial protection.2
The Fc isotype determines the immunological profile of the fusion:
IgG1: Strong effector functions (ADCC, CDC); suitable for cytotoxic mechanisms
IgG4: Minimal immune activation; preferred for blocking or neutralizing antibodies
Engineered Fc variants: Fc-silent or Fc-enhanced versions (e.g., S239D/I332E) for tailored activity
Choice of Fc must align with therapeutic goals and safety profiles.
To maintain functional independence between VHH and Fc domains, linkers are essential. Properties of effective linkers include:
Flexibility: (G4S)n repeats allow proper domain orientation
Length: Sufficient spacing prevents steric hindrance
Protease resistance: Stability in physiological conditions
Fc-fused VHHs are best expressed in mammalian cells (e.g., CHO, HEK293) to ensure:
Proper folding and disulfide bond formation
Native N-glycosylation at Asn297 in CH2 (affecting Fc receptor binding and half-life)
Scalability for GMP manufacturing
Although distinct from Fc fusion, enzyme fusion represents another VHH-based engineering strategy. VHHs can be fused to enzymes to create targeted catalytic agents with therapeutic or diagnostic functions. Applications include:
Lysosomal enzyme targeting: Fusion with VHH improves delivery and uptake in enzyme replacement therapies.
ADEPT (Antibody-Directed Enzyme Prodrug Therapy): VHH-enzyme fusions convert prodrugs into cytotoxic agents at the disease site, minimizing systemic toxicity.
VHH fusions offer superior tissue penetration and target specificity compared to full-size antibodies, reducing off-target enzymatic activity and systemic exposure.
Oncology
Fc-VHH fusions with ADCC/CDC activity enable immune-mediated tumor cell clearance. VHH-enzyme fusions deliver prodrug-converting enzymes selectively to tumor sites.
Autoimmune Diseases
Long-acting Fc-VHHs maintain immunomodulatory effects with reduced dosing frequency. Unwanted Fcγ receptor engagement can be reduced through Fc-silencing mutations.
Infectious Diseases
Fc-VHH constructs serve as neutralizing agents with extended half-life. Fusion with proteases or viral inhibitors enables targeted disruption of pathogen replication.
Toxin neutralization
In botulism models, VHH-Fc fusions provided long-term prophylaxis against BoNT/A. A single administration protected animals from lethal challenge even 14 days post-injection, demonstrating their suitability for passive immunization strategies.
Immunogenicity
Immunogenicity may arise from the VHH framework, non-human or engineered sequences, junctional regions, or non-native fusion partners. Humanization and glycoengineering strategies are used to minimize risk.
Function Preservation
Fusion design must maintain VHH affinity and Fc/enzyme activity. Improper linkers or folding can reduce therapeutic efficacy.
Expression Complexity
Multidomain constructs face increased risks of aggregation or misfolding. Proper expression systems and construct optimization are critical.
Size and steric effects
Fc domains (~50 kDa) can limit tissue penetration and access to sterically restricted or densely packed epitopes, areas where standalone VHHs may offer an advantage.
Computational Modeling
Structural prediction tools guide the selection of fusion sites and Fc variants to preserve function and stability.
AI-Assisted Linker Design
Machine learning identifies linker sequences that optimize flexibility, protease resistance, and inter-domain spacing.
High-Throughput Screening
Parallel production and secretion assays enable rapid evaluation of VHH-Fc and VHH-enzyme fusion candidates for expression, folding, and function.
These approaches support rational design and scalability for clinical development.
VHH Fc and enzyme fusions combine the unique targeting properties of VHHs with the functional advantages of Fc and enzymatic domains. These strategies enable:
Extended pharmacokinetics via FcRn recycling
Effector function modulation for immune recruitment
Enzyme delivery for localized therapeutic effects
Improved secretion of difficult-to-express proteins and peptides
Biointron supports VHH discovery and fusion protein design with a comprehensive platform for VHH library screening, affinity maturation, and expression-ready construct delivery - streamlining development of fusion-ready VHHs for therapeutic engineering.
What is a VHH Fc fusion?
A single-domain VHH antibody genetically fused to the Fc region of human IgG, combining targeting specificity with prolonged half-life and immune effector functions.
How does Fc fusion improve VHH antibody performance?
By increasing serum half-life through FcRn recycling and enabling effector functions such as ADCC and CDC, depending on the Fc isotype.
What are the benefits of fusing VHHs to enzymes?
It allows targeted enzymatic activity for therapeutic applications such as ADEPT or enzyme replacement, with reduced off-target toxicity.
Can VHH Fc fusions trigger immune responses?
Yes, especially if derived from non-human sources. However, humanized VHHs and Fc engineering can reduce immunogenicity.
What expression systems are used for producing VHH Fc fusion proteins?
Mammalian systems (e.g., CHO, HEK293) are preferred for proper glycosylation, folding, and high-yield expression.
How are linkers selected for VHH Fc fusion designs?
Flexible linkers like (G4S)n are commonly used to maintain structural independence and prevent functional interference between domains.
Abdeldaim, D. T., & Schindowski, K. (2023). Fc-Engineered Therapeutic Antibodies: Recent Advances and Future Directions. Pharmaceutics, 15(10), 2402. https://doi.org/10.3390/pharmaceutics15102402
Godakova, S. A., Noskov, A. N., Vinogradova, I. D., Ugriumova, G. A., Solovyev, A. I., Esmagambetov, I. B., Tukhvatulin, A. I., Logunov, D. Y., Naroditsky, B. S., Shcheblyakov, D. V., & Gintsburg, A. L. (2019). Camelid VHHs Fused to Human Fc Fragments Provide Long Term Protection Against Botulinum Neurotoxin A in Mice. Toxins, 11(8), 464. https://doi.org/10.3390/toxins11080464
Yan, R., Zhang, Y., Zhang, H., & Ma, J. (2025). Nanobody fusion enhances production of difficult-to-produce secretory proteins. The Journal of biological chemistry, 301(3), 108292. https://doi.org/10.1016/j.jbc.2025.108292
Günaydın, G., Yu, S., Gräslund, T., Hammarström, L., & Marcotte, H. (2016). Fusion of the mouse IgG1 Fc domain to the VHH fragment (ARP1) enhances protection in a mouse model of rotavirus. Scientific Reports, 6(1), 1-11. https://doi.org/10.1038/srep30171
In this article, we explore the major trends shaping the future of targeted canc……
Site-specific conjugation limits payload attachment to defined positions on the ……
Affinity maturation can improve binding to the intended target, but it can also ……
ADC development is no longer limited to the antibody-linker-toxin model. The fie……
You can also contact us on the Scientist and Science Exchange marketplaces.
